Effect of Apolipoprotein AI on MCP?1 Plasma Levels,Monocyte Subset Proportions,and in Vitro CCR2 Expression
10.12007/j.issn.0258?4646.2017.06.005
- VernacularTitle:载脂蛋白AI对单核细胞表型与MCP?1/CCR2的影响
- Author:
Jianguo YIN
;
Shebing ZHANG
;
Daoquan PENG
- Keywords:
apolipoprotein AI;
monocyte subset;
monocyte chemotactic protein 1;
CC?chemokine receptor 2
- From:
Journal of China Medical University
2017;46(6):501-504
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore effects of apoAI on MCP?1 levels in the plasma and the Ly6Chi monocyte proportion in the blood and spleen of atherosclerotic mice,as well as on CCR2 expression in vitro. Methods Sixteen male apoE?/?mice were fed with high cholesterol diet for 12 weeks. Mice were randomly divided into control and apoAI groups and were administered with PBS or apoAI(40 mg/kg),respectively,via tail vein on the 1st and 3rd day before sacrifice. Mice in both groups were administered LPS(25μg/mouse)via intraperitoneal injection 12 h before sacrifice. Plas?ma levels of MCP?1 were determined using ELISA,and the Ly6Chi monocyte proportion was analyzed using flow cytometry. In addition,human monocytic THP?1 cells were randomly divided into control and apoAI(10 mg/L)?treated groups,pretreated with corresponding intervention,and incubated with LPS(10μg/L). CCR2 expression levels were measured by Western blotting. Results Compared with the control treatment, apoAI treatment remarkably reduced MCP?1 levels in plasma and Ly6Chi monocyte proportion in the blood and spleen(P<0.01). Furthermore, apoAI treatment inhibited CCR2 expression in monocytes in vitro(P<0.05). Conclusion apoAI can reduce MCP?1 levels in plasma and the Ly6Chi monocyte proportion in the blood and spleen and can inhibit CCR2 expression in monocytes in vitro.
